16
Participants
Start Date
August 27, 2021
Primary Completion Date
June 29, 2022
Study Completion Date
June 29, 2022
THR-687 dose level 1
3 intravitreal injections of THR-687 dose level 1, 1 month apart
THR-687 dose level 2
3 intravitreal injections of THR-687 dose level 2, 1 month apart
THR-687 selected dose level
3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
Aflibercept
3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
Szegedi Tudományegyetem, Szeged
Ganglion Medical Center, Pécs
Eye Clinic Dr Krista Turman, Tallinn
Silmalaser OU, Tallinn
Retina Vitreous Surgeons of Central New York, PC, Liverpool
Eye Care Specialists, Kingston
Cumberland Valley Retina Consultants, Hagerstown
Tennessee Retina, PC, Nashville
Retina Associates, Ltd, Elmhurst
University Retina and macula Associates, PC, Oak Forest
Tulsa Retina Consultants, Tulsa
Strategic Clinical Research Group, Willow Park
Retina Center of Texas, Southlake
Retina Consultants of Texas, Katy
Medical Center Ophthalmology Associates, San Antonio
Valley Retina Institute, P.A., McAllen
Austin Research Center of Retina, Austin
Retina Consultants of Southern Colorado, P.C., Colorado Springs
Sierra Eye Associates, Reno
California Eye Specialists Medical Group, Inc., Pasadena
Salehi Retina Institute Inc., Huntington Beach
Retinal Consultants Medical Group, Sacramento
Pauls Stradins Clinical University Hospital, Riga
Riga East Clinical University Hospital, Riga
Vilnius University Hospital Santaros klinikos, Vilnius
Lead Sponsor
Oxurion
INDUSTRY